Brief: Paratek Announces License Grant To Almirall For Seysara For Greater China Region
24/02/2020 12:20
Feb 24 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK ANNOUNCES LICENSE GRANT TO ALMIRALL FOR SEYSARA®
(SARECYCLINE) FOR GREATER CHINA REGION
* PARATEK PHARMACEUTICALS INC - WILL EARN HIGH SINGLE-DIGIT
ROYALTIES ON NET SALES IN GREATER CHINA REGION
* PARATEK PHARMA -ALMIRALL PLANS TO DEVELOP SARECYCLINE FOR
ACNE
IN CHINA, WITH POTENTIAL SUBMISSION TO CHINA NATIONAL MEDICAL
PRODUCTS ADMINISTRATION IN 2023
Source text for Eikon: ID:nGNX7QlJp6
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million